First author, year [ref.] | Phase | Patients | Arms | PFS months | p-value | OS months | p-value | Response rate % | p-value |
Pallis, 2010 [23] | III | 132 | Docetaxel + carboplatin | 3.33 | 0.012 | 10.3 | 0.55 | 10.4 | 0.764 |
Docetaxel | 2.60 | 7.70 | 7.7 | ||||||
Takeda, 2009 [22] | III | 130 | Docetaxel + gemcitabine | 2.8 | 0.028 | 10.3 | 0.36 | 7.0 | 0.71 |
Docetaxel | 2.1 | 10.1 | 6.8 | ||||||
Gebbia, 2009 [5] | III | 84 | Docetaxel | 12.4 weeks | 0.44 | 40 weeks | 0.18 | 6.4 | NR |
Docetaxel + vinorelbine or gemcitabine | 13.1 weeks | 0.60 | 32.6 weeks | 0.90 | 16.7 | ||||
Docetaxel + capecitabine | 11.9 weeks | 39.7 weeks | 5.3 | ||||||
Ardizzoni, 2012 [25] | II | 479 | Pemetrexed + carboplatin | 3.9 | 0.70 | 8.7 | 0.316 | 15 | 0.062 |
Pemetrexed | 3.0 | 8.2 | 9 | ||||||
Smit, 2009 [24] | II | 240 | Pemetrexed + carboplatin | 4.2 | 0.005 | 8.0 | ns | 9 | ns |
Pemetrexed | 2.8 | 7.6 | 4 | ||||||
Pectasides, 2005 [26] | II | 130 | Docetaxel + irinotecan | 5.6 | 0.065 | 6.5 | 0.49 | 20 | 0.36 |
Docetaxel | 4.8 | 6.4 | 14 | ||||||
Wachters, 2005 [27] | II | 108 | Docetaxel + irinotecan | 15 weeks | 0.42 | 27 weeks | 0.69 | 10 | NR |
Docetaxel | 18 weeks | 32 weeks | 16 | ||||||
Georgoulias, 2005 [30] | II | 147 | Cisplatin + irinotecan | NR | NR | 7.8 | 0.934 | 22.5 | 0.012 |
Cisplatin | 8.8 | 7 |
Data are presented as n, unless otherwise stated. PFS: progression-free survival; OS: overall survival; NR: not reported; ns: nonsignificant.